GlassScriptPhysician profile
Dollie A Husfeld
NPI 1043339336
$6,850.56
in general payments reported to CMS, 2019-2025
48 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,574 · 2022: $1,177 · 2023: $1,243 · 2024: $724 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,098.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,121.53 | 2021-2025 | Otezla, Repatha, Otezla |
| Abbvie INC. | $821.52 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $526.68 | 2021-2025 | Calquence, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $325.10 | 2021-2025 | Austedo Xr, Austedo, Ajovy |
| Lilly USA, LLC | $307.95 | 2021-2025 | Mounjaro, Zepbound, Jaypirca |
| Novo Nordisk INC | $292.20 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $292.08 | 2023-2025 | |
| Pfizer INC. | $188.08 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $145.34 | 2023-2025 | Gemtesa |
| Glaxosmithkline, LLC. | $131.12 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $127.82 | 2021-2022 | |
| Amarin Pharma, INC. | $118.80 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.94 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $92.22 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $88.69 | 2021-2025 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dollie Husfeld listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.